72
Participants
Start Date
June 1, 2022
Primary Completion Date
October 31, 2024
Study Completion Date
June 30, 2026
Axitinib Oral Tablet [Inlyta]
Axitinib 5 up to 10mg twice a day
Pembrolizumab Injection [Keytruda]
Pembrolizumab intravenously over 30 min minutes at 200 mg every 3 weeks
RECRUITING
Institut Paoli-Calmettes, Marseille
NOT_YET_RECRUITING
CHU de BESANCON, Besançon
RECRUITING
Iuct-Oncopole Institut Claudius Regaud, Toulouse
RECRUITING
Chu Bordeaux, Bordeaux
NOT_YET_RECRUITING
Ico-Rene Gauducheau, Saint-Herblain
NOT_YET_RECRUITING
Ico - Paul Papin, Angers
RECRUITING
Institut de Cancerologie de Lorraine - Alexis Vautrin, Vandœuvre-lès-Nancy
NOT_YET_RECRUITING
Centre Jean Perrin, Clermont-Ferrand
RECRUITING
Centre Leon Berard, Lyon
NOT_YET_RECRUITING
Ap-Hp Hôpital Europeen Georges Pompidou, Paris
RECRUITING
Gustave Roussy, Villejuif
RECRUITING
Centre Antoine Lacassagne, Nice
Centre Leon Berard
OTHER